During its presentation at the 44th Annual J.P. Morgan Healthcare Conference, Alnylam Pharmaceuticals underscored progress across its RNAi platform, detailing clinical updates for five late-stage programs. The company provided data on its investigational therapies for hereditary ATTR polyneuropathy and cardiomyopathy, reporting sustained reductions in transthyretin levels of up to 95% in Phase III trials. Senior management also discussed expansion plans for manufacturing capacity in Norton, Massachusetts, with a planned doubling of GMP production slots by 2025 to support global launches.

In unveiling its 'Alnylam 2030' five-year roadmap, the company set a goal of achieving durable global leadership in transthyretin (TTR) disease treatment. Key to this strategy is the planned launch of nucresiran, an investigational subcutaneous therapy expected to reach regulatory submission between 2028 and 2030. Alnylam detailed reagent supply agreements with two third-party CDMOs and anticipates initiating six Phase II and III studies across hereditary and wild-type ATTR cohorts by year-end 2024.

Alnylam projected net product revenues of $4.9 to $5.3 billion for fiscal 2026, representing year-over-year growth of approximately 71% relative to 2023. Within this, the TTR franchise is expected to contribute $4.4 to $4.7 billion, driven by increasing market penetration of its existing RNAi therapies and the staged rollout of next-generation candidates. These guidance figures exceed consensus analyst estimates by roughly 15%, reflecting higher assumed uptake rates in North America and Western Europe.

Despite the robust guidance, Alnylam shares declined by 10% on the Monday following the announcement, as reported trading volumes surged to twice the 30-day average. Some investors expressed concern that 2025 revenue projections, while still signaling strong double-digit growth, narrowly missed Street forecasts. Market commentators noted that the timing of nucresiran’s launch and potential pricing pressures in Europe represent key execution risks for the company’s long-term outlook.